Evidence map›Paper›PMID 17898795›Full record

ArticleGene therapy2007

Pulmonary delivery of adenovirus vector formulated with dexamethasone-spermine facilitates homologous vector re-administration.

A R Price, M P Limberis, J M Wilson, S L Diamond

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Advances in cell and gene-based therapies for cystic fibrosis lung disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2012
    Review
  4. Article
  5. Article
  6. Article
  7. Cationic lipid formulations alter the in vivo tropism of AAV2/9 vector in lung.Molecular therapy : the journal of the American Society of Gene Therapy · 2009
    Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

A R PriceDepartment of Bioengineering, Institute for Medicine and Engineering, Vagelos Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA.
M P Limberis
J M Wilson
S L Diamond
University of Pennsylvania · US

Funding

Vector CoreP30DK047757 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI WILSON, JAMES M · 1993 to 2017
$18.0M
MECHANISMS OF NONVIRAL CARDIOVASCULAR GENE TRANSFERR01HL066565 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI DIAMOND, SCOTT L · 2001 to 2013
$3.6M
NHLBI NIH HHS HL66565NIDDK NIH HHS P30 DK047757
6 · The paper itself

Abstract

Gene transfer to lung has been hindered by inflammatory and immunological responses activated to the gene-transfer agent or transgene products. In prior work, adenovirus vector delivered to the lung with the cationic glucocorticoid, dexamethasone-spermine (DS) had improved targeting to conducting airway epithelium and reduced cellular infiltration. In this study, the effect of formulation on homologous adenovirus vector re-administration was studied in C57Bl/6 mice. Formulation of an adenovirus vector expressing LacZ with DS/dioleoylphosphatidylethanolamine (DOPE) delivered at day 0 allowed re-administration of adenovirus vector expressing alkaline phosphatase at day 21. Formulation with 3beta [N-(N', N'-dimethylaminoethane) carbamoy] cholesterol (DC-Chol) DC-cholesterol (DC-Chol))/DOPE or dexamethasone in the first dosing at day 0 resulted in moderate alkaline phosphatase expression at day 24. Neutralizing antibodies against adenovirus vector in serum at day 28 were greatly reduced by all three formulations in mice receiving a single dose of adenovirus at day 0. Also, homologous adenovirus vector re-administration at day 14 produced less neutralizing antibody at day 28 when adenovirus was formulated with DS/DOPE at day 0. The use of DS/DOPE at day 0 dramatically reduced CD4 and CD8 T-cell infiltration in mice receiving adenovirus at day 0 followed by vector re-administration at day 14. Transgene-specific T-cell activation was markedly reduced by the DC-Chol/DOPE formulation. Overall, DS/DOPE) facilitated homologous vector re-administration through a combination of liposomal and glucocorticoid mechanisms.

Indexed as

AdenoviridaeAlkaline PhosphataseAnimalsAntibodiesCholesterolCystic FibrosisDexamethasoneGene ExpressionGenetic EngineeringGenetic TherapyGenetic VectorsImmunosuppressive AgentsLiposomesLungLymphocyte ActivationMice1,2-dioleoyl-glycero-3-phosphatidyl ethanolamine3-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterolAlkaline PhosphataseAntibodiesCholesterolDexamethasoneImmunosuppressive AgentsLiposomesPhosphatidylethanolaminesSpermine

Identifiers

PMID17898795
OpenAlexW2167125445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.